Sirion Sells Zirgan Rights to Bausch & Lomb

Sirion Therapeutics Inc. has sold the assets and U.S. rights for Zirgan, a topical anti-viral for the treatment of corneal ulcers, to Bausch + Lomb. No financial terms were disclosed. Sirion is a Tampa, Fla.-based drug company focused on ophthalmic products. It has raised over $45 million in VC funding from Aisling Capital, Investor Growth Capital, Atlas Venture, Advent International, Bear Sterns Healthcare Value Partners and NovaQuest.